Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
COVID-19 Serotherapy
Transfer of blood plasma derived from patients who have recovered from COVID-19 to non-immune hosts.
Year introduced: 2023 (2020)
COVID-19 Testing
Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence of COVID-19 antibodies, SARS-COV-2 antigens or the VIRAL RNA of SARS-COV-2.
Year introduced: 2021
COVID-19 Vaccines
Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19.
COVID-19 Serological Testing
Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence antibodies specific to SARS-COV-2 or its antigens.
COVID-19 Nucleic Acid Testing
Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence of the VIRAL RNA of SARS-COV-2.
COVID-19
A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.
Year introduced: 2021(2020)
SARS-CoV-2
A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis.
2019-nCoV Vaccine mRNA-1273
mRNA vaccine against SARS-CoV-2, developed by Moderna.
Year introduced: 2022(2021)
Post-Acute COVID-19 Syndrome
Post acute stage of COVID-19 virus infection. Persistent symptoms may include FATIGUE; DYSPNEA; and MEMORY LOSS.
Year introduced: 2023(2020)
COVID-19 Drug Treatment
The use of DRUGS to treat COVID19 or its symptoms.
ChAdOx1 nCoV-19
A viral vector vaccine against SARS-CoV-2 developed by AstraZeneca. Its vector encodes the SARS-CoV-2 Spike protein.
SARS-CoV-2 variants [Supplementary Concept]
Sequence variants of SARS-COV-2 virus when compared to the reference sequence (NC_045512.2). Many are under investigation for various mutations and their potential impact on COVID-19 (e.g, transmissibility, diagnosis, vaccine effectiveness or clinical presentation or severity). For instance variant B.1.1.7 is characterized by a set of mutations including N501Y on the spike protein which binds human ACE2 PROTEIN. There are more than 900 registered variants as of February 2021.
Date introduced: December 21, 2020
spike protein, SARS-CoV-2 [Supplementary Concept]
Date introduced: March 19, 2020
pediatric multisystem inflammatory disease, COVID-19 related [Supplementary Concept]
Paediatric multisystem inflammatory syndrome temporally associated with COVID-19
Date introduced: May 10, 2020
Baiya SARS-CoV-2 VAX COVID-19 vaccine [Supplementary Concept]
plant (Nicotiana benthamiana) produced SARS-CoV-2 receptor binding domain protein subunit vaccine
Date introduced: May 25, 2022
nucleocapsid phosphoprotein, SARS-CoV-2 [Supplementary Concept]
RefSeq NC_045512
Date introduced: October 1, 2020
adult multisystem inflammatory disease, COVID-19 related [Supplementary Concept]
Date introduced: July 8, 2021
3C-like proteinase, SARS-CoV-2 [Supplementary Concept]
Date introduced: September 30, 2020
Ad5-nCoV vaccine [Supplementary Concept]
Pandemic Preparedness
Various plans outlined for the care of casualties and the maintenance of services in a PANDEMIC. Pandemic preparedness plan includes CAPACITY BUILDING in flexible infrastructure and SENTINEL SURVEILLANCE.
Year introduced: 2024